eszopiclone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
hypnotic tranquillizers 1068 138729-47-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • eszopiclone
  • esopiclone
  • lunesta
A pyridine, pyrazine, and piperazine derivative that is used as a HYPNOTIC AND SEDATIVE in the treatment of INSOMNIA.
  • Molecular weight: 388.81
  • Formula: C17H17ClN6O3
  • CLOGP: 1.25
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 0
  • TPSA: 91.76
  • ALOGS: -2.64
  • ROTB: 3
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.11 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.743 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 2.249 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 20.464 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 2.382 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 76.760 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 78.290 % High 1
herg hERG pIC50 4.653 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.199 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 7.362 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 66.720 % High 1
kinase-safety-class EIF2AK3,GRK2,PDK1,PDK2,PDK4 5
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 5.702 High 1
mh-clint Mouse hepatocyte intrinsic clearance 5.070 High 1
mppb Mouse plasma protein binding (% unbound) 66.100 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 23.014 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 79.020 % High 1
rh-clint Rat hepatocyte intrinsic clearance 3.334 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 89.790 % High 1
rppb Rat plasma protein binding (% unbound) 63.850 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 926.830 uM High 1

Approvals:

DateAgencyCompanyOrphan
Dec. 15, 2004 FDA SUNOVION PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dysgeusia 751.01 12.15 311 18083 52249 90557804
Completed suicide 375.05 12.15 277 18117 144781 90465272
Insomnia 102.94 12.15 216 18178 333258 90276795
Middle insomnia 90.58 12.15 51 18343 16700 90593353
Overdose 80.28 12.15 127 18267 157582 90452471
Parasomnia 79.79 12.15 20 18374 656 90609397
Suicidal ideation 77.62 12.15 85 18309 73770 90536283
Nightmare 61.67 12.15 44 18350 21681 90588372
Depression 61.47 12.15 166 18228 300435 90309618
Anxiety 59.31 12.15 167 18227 309605 90300448
Toxicity to various agents 57.89 12.15 158 18236 287688 90322365
Cardio-respiratory arrest 55.07 12.15 66 18328 63074 90546979
Respiratory arrest 54.86 12.15 49 18345 33262 90576791
Synovitis 54.72 12.15 3 18391 329749 90280304
Somnambulism 53.90 12.15 26 18368 6202 90603851
Hand deformity 48.24 12.15 3 18391 296359 90313694
Suicide attempt 47.31 12.15 67 18327 75332 90534721
Contraindicated product administered 47.25 12.15 5 18389 320134 90289919
Treatment failure 46.83 12.15 4 18390 303924 90306129
Glossodynia 45.08 12.15 6 18388 321773 90288280
Intentional overdose 44.21 12.15 73 18321 93761 90516292
Drug intolerance 43.85 12.15 18 18376 447573 90162480
Systemic lupus erythematosus 43.62 12.15 10 18384 361886 90248167
Joint swelling 43.56 12.15 24 18370 503276 90106777
Maternal exposure during pregnancy 41.35 12.15 11 18383 360052 90250001
Somnolence 40.24 12.15 113 18281 208971 90401082
Cardiac arrest 39.54 12.15 74 18320 104861 90505192
Lower respiratory tract infection 39.44 12.15 3 18391 250656 90359397
Tremor 39.01 12.15 92 18302 153081 90456972
Wound 37.26 12.15 8 18386 302972 90307081
Infusion related reaction 34.44 12.15 21 18373 416759 90193294
Altered state of consciousness 34.35 12.15 37 18357 31495 90578558
Fall 33.56 12.15 189 18205 481621 90128432
Abnormal dreams 32.41 12.15 23 18371 11234 90598819
Arthropathy 32.34 12.15 17 18377 366225 90243828
Initial insomnia 31.47 12.15 21 18373 9289 90600764
Paradoxical drug reaction 29.67 12.15 17 18377 5749 90604304
General physical health deterioration 29.18 12.15 18 18376 355097 90254956
Agitation 28.69 12.15 50 18344 67048 90543005
Ill-defined disorder 26.98 12.15 3 18391 184888 90425165
Seizure 26.94 12.15 80 18314 152549 90457504
Hallucination 26.71 12.15 48 18346 65911 90544142
Alopecia 26.63 12.15 37 18357 495034 90115019
Brain death 26.61 12.15 14 18380 4007 90606046
Abnormal sleep-related event 26.55 12.15 9 18385 862 90609191
Irritable bowel syndrome 24.45 12.15 6 18388 207442 90402611
Restlessness 24.28 12.15 33 18361 35687 90574366
Wheezing 24.24 12.15 9 18385 238071 90371982
Suspected suicide 24.03 12.15 18 18376 9550 90600503
Type 2 diabetes mellitus 23.72 12.15 6 18388 203238 90406815
Unresponsive to stimuli 22.62 12.15 33 18361 38088 90571965
Dehydration 22.10 12.15 88 18306 194359 90415694
Concussion 21.68 12.15 18 18376 11073 90598980
Hangover 21.59 12.15 10 18384 2179 90607874
Hallucination, visual 21.55 12.15 25 18369 23067 90586986
Hypersensitivity 21.55 12.15 37 18357 454640 90155413
Hepatic enzyme increased 21.42 12.15 25 18369 360711 90249342
Product dose omission issue 21.32 12.15 116 18278 291571 90318482
Product substitution issue 21.15 12.15 22 18372 17986 90592067
Feeling abnormal 20.90 12.15 78 18316 167157 90442896
Urea cycle disorder 20.52 12.15 4 18390 39 90610014
Encephalopathy 20.36 12.15 35 18359 46409 90563644
Dissociation 19.98 12.15 14 18380 6701 90603352
Irritability 19.91 12.15 30 18364 35632 90574421
Palpitations 19.85 12.15 67 18327 136661 90473392
Product use issue 19.44 12.15 23 18371 329896 90280157
Amnesia 19.26 12.15 57 18337 108448 90501605
Electrocardiogram QRS complex prolonged 18.85 12.15 14 18380 7334 90602719
Abnormal behaviour 18.66 12.15 23 18371 22605 90587448
Blastocystis infection 18.25 12.15 4 18390 72 90609981
Swelling 18.17 12.15 36 18358 419022 90191031
Discomfort 17.39 12.15 18 18376 274317 90335736
Areflexia 16.76 12.15 10 18384 3643 90606410
Nausea 16.76 12.15 317 18077 1109999 89500054
Pre-existing condition improved 16.12 12.15 14 18380 9155 90600898
Abdominal discomfort 15.95 12.15 47 18347 477281 90132772
Exposure during pregnancy 15.85 12.15 15 18379 238395 90371658
Restless legs syndrome 15.64 12.15 21 18373 22449 90587604
Akathisia 15.63 12.15 15 18379 11144 90598909
Dyskinesia 15.32 12.15 27 18367 36507 90573546
Drug ineffective 14.77 12.15 376 18018 1383922 89226131
Inflammation 14.73 12.15 9 18385 178583 90431470
Off label use 14.72 12.15 148 18246 1102104 89507949
Lipid metabolism disorder 14.61 12.15 4 18390 186 90609867
Sleep-related eating disorder 14.50 12.15 6 18388 998 90609055
Psoriatic arthropathy 14.45 12.15 15 18379 228320 90381733
Nasopharyngitis 14.40 12.15 39 18355 407065 90202988
Tooth disorder 14.38 12.15 24 18370 31066 90578987
Foot fracture 14.31 12.15 22 18372 26584 90583469
Peripheral swelling 14.29 12.15 40 18354 413066 90196987
Ventricular tachyarrhythmia 14.19 12.15 4 18390 207 90609846
Impaired healing 14.14 12.15 16 18378 234183 90375870
Carbon monoxide poisoning 14.08 12.15 4 18390 213 90609840
Sleep apnoea syndrome 14.01 12.15 24 18370 31723 90578330
Emotional distress 13.98 12.15 26 18368 36636 90573417
Multiple sclerosis relapse 13.94 12.15 32 18362 52273 90557780
C-reactive protein increased 13.80 12.15 10 18384 181379 90428674
Malignant catatonia 13.75 12.15 4 18390 232 90609821
Dizziness 13.70 12.15 181 18213 589103 90020950
Anterograde amnesia 13.63 12.15 5 18389 604 90609449
Respiratory acidosis 13.48 12.15 12 18382 8107 90601946
Dermatitis atopic 13.46 12.15 20 18374 23452 90586601
Hyperhidrosis 13.38 12.15 59 18335 136246 90473807
Bursitis 13.35 12.15 5 18389 131649 90478404
Pneumonia aspiration 13.14 12.15 27 18367 40913 90569140
Panic attack 13.07 12.15 21 18373 26344 90583709
Drug withdrawal syndrome 13.06 12.15 22 18372 28701 90581352
Acute psychosis 13.03 12.15 8 18386 3070 90606983
Delusion 12.94 12.15 15 18379 13825 90596228
Blister 12.77 12.15 20 18374 254978 90355075
Wound infection 12.68 12.15 3 18391 106399 90503654
Incorrect dose administered 12.64 12.15 40 18354 78890 90531163
Ankle fracture 12.62 12.15 18 18376 20352 90589701
Gait inability 12.62 12.15 7 18387 146449 90463604
Bipolar disorder 12.44 12.15 12 18382 8973 90601080
Implant site erosion 12.32 12.15 3 18391 87 90609966
Multiple sclerosis 12.23 12.15 21 18373 27819 90582234
Mental impairment 12.21 12.15 16 18378 16704 90593349
Tardive dyskinesia 12.21 12.15 13 18381 10917 90599136

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dysgeusia 296.21 14.20 146 9187 34043 42577959
Completed suicide 206.84 14.20 170 9163 96295 42515707
Insomnia 79.79 14.20 113 9220 118140 42493862
Suicide attempt 70.08 14.20 67 9266 46033 42565969
Parasomnia 69.97 14.20 17 9316 452 42611550
Middle insomnia 66.35 14.20 33 9300 7800 42604202
Initial insomnia 59.51 14.20 25 9308 4005 42607997
Somnolence 41.70 14.20 94 9239 141011 42470991
Somnambulism 36.87 14.20 17 9316 3398 42608604
Altered state of consciousness 34.34 14.20 37 9296 29222 42582780
Suicidal ideation 33.85 14.20 47 9286 48114 42563888
Overdose 33.19 14.20 72 9261 105192 42506810
Drug ineffective 31.38 14.20 240 9093 629957 41982045
Anxiety 28.55 14.20 73 9260 118487 42493515
Foreign body aspiration 25.26 14.20 7 9326 315 42611687
Dissociation 23.58 14.20 13 9320 3785 42608217
Hepatic function abnormal 19.44 14.20 38 9295 51529 42560473
Depression 19.39 14.20 61 9272 111302 42500700
Sternal fracture 18.59 14.20 7 9326 842 42611160
Abnormal dreams 18.53 14.20 15 9318 8256 42603746
Nightmare 18.46 14.20 25 9308 24987 42587015
Intentional overdose 18.30 14.20 37 9296 51419 42560583
Acute kidney injury 18.16 14.20 33 9300 367304 42244698
Sleep apnoea syndrome 18.12 14.20 23 9310 21585 42590417
Interstitial lung disease 17.53 14.20 47 9286 78415 42533587
Gun shot wound 17.23 14.20 7 9326 1030 42610972
Soliloquy 16.79 14.20 6 9327 623 42611379
Pneumonia aspiration 16.62 14.20 35 9298 50043 42561959
Hallucination 16.60 14.20 38 9295 57469 42554533
Amnesia 14.62 14.20 24 9309 28413 42583589

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dysgeusia 602.19 12.03 286 21070 69699 110498244
Completed suicide 589.62 12.03 437 20919 241944 110325999
Parasomnia 124.05 12.03 29 21327 742 110567201
Middle insomnia 107.13 12.03 60 21296 20442 110547501
Suicide attempt 96.16 12.03 109 21247 103285 110464658
Insomnia 89.70 12.03 208 21148 360382 110207561
Overdose 86.63 12.03 159 21197 233635 110334308
Initial insomnia 75.81 12.03 38 21318 10351 110557592
Somnambulism 73.36 12.03 32 21324 6373 110561570
Respiratory arrest 71.09 12.03 71 21285 58228 110509715
Altered state of consciousness 69.94 12.03 70 21286 57556 110510387
Somnolence 58.54 12.03 157 21199 297292 110270651
Intentional overdose 51.42 12.03 92 21264 132409 110435534
Suicidal ideation 51.10 12.03 76 21280 93861 110474082
Toxicity to various agents 50.57 12.03 205 21151 480350 110087593
Cardio-respiratory arrest 46.97 12.03 82 21274 115754 110452189
Nightmare 44.94 12.03 46 21310 38817 110529126
Depression 43.07 12.03 147 21209 317188 110250755
Anxiety 42.66 12.03 155 21201 344923 110223020
Dissociation 38.77 12.03 24 21332 9818 110558125
Hepatic function abnormal 38.55 12.03 65 21291 89230 110478713
Cardiac arrest 37.81 12.03 103 21253 196650 110371293
Treatment failure 36.74 12.03 5 21351 277229 110290714
Lower respiratory tract infection 35.74 12.03 3 21353 243103 110324840
Drug intolerance 35.58 12.03 17 21339 406495 110161448
Joint swelling 35.13 12.03 21 21335 442824 110125119
Pneumonia aspiration 34.89 12.03 59 21297 81174 110486769
Abnormal dreams 33.07 12.03 24 21332 12756 110555187
General physical health deterioration 32.58 12.03 21 21335 425274 110142669
Hand deformity 31.30 12.03 3 21353 218503 110349440
Interstitial lung disease 30.93 12.03 77 21279 139257 110428686
Restlessness 27.05 12.03 43 21313 56216 110511727
Fall 26.94 12.03 204 21152 603278 109964665
Foreign body aspiration 26.90 12.03 8 21348 527 110567416
Maternal exposure during pregnancy 26.73 12.03 8 21348 254875 110313068
Pericarditis 26.67 12.03 5 21351 219109 110348834
Systemic lupus erythematosus 26.64 12.03 8 21348 254330 110313613
Infusion related reaction 26.33 12.03 21 21335 381141 110186802
Off label use 26.30 12.03 176 21180 1500009 109067934
Hallucination 25.68 12.03 59 21297 101373 110466570
Paradoxical drug reaction 24.42 12.03 18 21338 9799 110558144
Arthropathy 23.69 12.03 13 21343 287509 110280434
Brain death 23.32 12.03 15 21341 6558 110561385
Anterograde amnesia 22.92 12.03 8 21348 880 110567063
Acute kidney injury 22.11 12.03 57 21299 635373 109932570
Amnesia 22.08 12.03 57 21299 105351 110462592
Wound 21.76 12.03 9 21347 234428 110333515
Glossodynia 21.47 12.03 8 21348 221996 110345947
Hangover 20.79 12.03 10 21346 2492 110565451
Contraindicated product administered 20.78 12.03 11 21345 248256 110319687
Ill-defined disorder 20.37 12.03 3 21353 156850 110411093
Folliculitis 20.03 12.03 4 21352 167649 110400294
Suspected suicide 19.43 12.03 19 21337 15180 110552763
Abnormal sleep-related event 19 12.03 7 21349 899 110567044
Abnormal behaviour 18.98 12.03 30 21326 39009 110528934
Drug ineffective 18.83 12.03 404 20952 1520136 109047807
Irritability 18.28 12.03 33 21323 47776 110520167
Agitation 17.68 12.03 55 21301 112996 110454947
Gun shot wound 17.61 12.03 7 21349 1105 110566838
Muscle injury 17.59 12.03 3 21353 140804 110427139
Irritable bowel syndrome 17.49 12.03 5 21351 164210 110403733
Blastocystis infection 17.35 12.03 4 21352 96 110567847
Sleep talking 16.72 12.03 7 21349 1261 110566682
Wheezing 16.47 12.03 15 21341 255215 110312728
Poisoning 16.47 12.03 24 21332 29081 110538862
Tremor 16.46 12.03 80 21276 202152 110365791
Blister 16.37 12.03 12 21344 227364 110340579
Dehydration 16.31 12.03 101 21255 279410 110288533
Pre-existing condition improved 16.31 12.03 12 21344 6514 110561429
Hallucination, visual 16.00 12.03 28 21328 39577 110528366
Akathisia 15.82 12.03 18 21338 17095 110550848
Thrombocytopenia 15.72 12.03 27 21329 348858 110219085
Disorientation 15.61 12.03 39 21317 70632 110497311
Sleep apnoea syndrome 15.57 12.03 28 21328 40419 110527524
Seizure 15.56 12.03 84 21272 221101 110346842
Delirium 15.28 12.03 59 21297 134966 110432977
Product use in unapproved indication 14.88 12.03 41 21315 447336 110120607
Psoriatic arthropathy 14.67 12.03 10 21346 196751 110371192
Soliloquy 14.66 12.03 6 21350 1021 110566922
Exposure during pregnancy 14.64 12.03 7 21349 167417 110400526
Type 2 diabetes mellitus 14.61 12.03 8 21348 177224 110390719
Product substitution issue 14.50 12.03 20 21336 23041 110544902
Electrocardiogram QRS complex prolonged 14.31 12.03 15 21341 13006 110554937
Blood cholesterol increased 14.30 12.03 9 21347 184776 110383167
Urea cycle disorder 14.23 12.03 3 21353 47 110567896
Tardive dyskinesia 13.79 12.03 15 21341 13564 110554379
Bursitis 13.76 12.03 4 21352 129914 110438029
Areflexia 13.74 12.03 11 21345 6758 110561185
Palpitations 13.69 12.03 64 21292 159148 110408795
Depressed level of consciousness 13.48 12.03 50 21306 112228 110455715
Hepatic enzyme increased 13.42 12.03 26 21330 320866 110247077
Impaired healing 13.37 12.03 11 21345 196706 110371237
Feeling abnormal 12.96 12.03 69 21287 180642 110387301
Inflammation 12.90 12.03 11 21345 193227 110374716
Hypersensitivity 12.72 12.03 38 21318 403960 110163983
Swelling 12.57 12.03 31 21325 351010 110216933
Carbon monoxide poisoning 12.34 12.03 4 21352 351 110567592

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05CF04 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Benzodiazepine related drugs
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D006993 Hypnotics and Sedatives
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35488 central nervous system depressant
CHEBI has role CHEBI:35717 sedative

Related Drugs by ATC class:

N05CF Benzodiazepine related drugs 3 drugs
zaleplonzolpidemzopiclone

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Insomnia indication 193462001
Suicidal thoughts contraindication 6471006
Asthenia contraindication 13791008
Alcohol intoxication contraindication 25702006
Depressive disorder contraindication 35489007
Hepatic failure contraindication 59927004
Sleep automatism contraindication 247962006
Severe chronic obstructive pulmonary disease contraindication 313299006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.95 Basic
pKa2 2.26 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
GABA A receptor alpha-5/beta-2/gamma-3 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL
Gamma-aminobutyric acid receptor subunit alpha-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 6.94 CHEMBL CHEMBL
GABA A receptor alpha-3/beta-2/gamma-3 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL
GABA A receptor alpha-5/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL
Gamma-aminobutyric acid receptor subunit alpha-4 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 6.99 CHEMBL CHEMBL
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL
GABA-A receptor alpha-1/beta-2/gamma-3 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL
GABA A receptor alpha-3/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL
Gamma-aminobutyric acid receptor subunit alpha-3 Ion channel Ki 6.79 CHEMBL
Gamma-aminobutyric acid receptor subunit alpha-1 Ion channel Ki 7.30 CHEMBL

External reference:

IDSource
4024906 VUID
N0000175354 NUI
D02624 KEGG_DRUG
4024906 VANDF
C1436328 UMLSCUI
CHEBI:53760 CHEBI
ZPC PDB_CHEM_ID
CHEMBL1522 ChEMBL_ID
DB00402 DRUGBANK_ID
D000069582 MESH_DESCRIPTOR_UI
969472 PUBCHEM_CID
7429 IUPHAR_LIGAND_ID
8258 INN_ID
UZX80K71OE UNII
461016 RXNORM
19107 MMSL
216714 MMSL
64025 MMSL
d05421 MMSL
008781 NDDF
409420000 SNOMEDCT_US
409421001 SNOMEDCT_US
UZX80K71OE INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Eszopiclone HUMAN PRESCRIPTION DRUG LABEL 1 0093-5537 TABLET, FILM COATED 1 mg ORAL ANDA 30 sections
Eszopiclone HUMAN PRESCRIPTION DRUG LABEL 1 0093-5538 TABLET, FILM COATED 2 mg ORAL ANDA 30 sections
Eszopiclone HUMAN PRESCRIPTION DRUG LABEL 1 0093-5539 TABLET, FILM COATED 3 mg ORAL ANDA 30 sections
Eszopiclone HUMAN PRESCRIPTION DRUG LABEL 1 0378-5270 TABLET, FILM COATED 1 mg ORAL ANDA 32 sections
Eszopiclone HUMAN PRESCRIPTION DRUG LABEL 1 0378-5271 TABLET, FILM COATED 2 mg ORAL ANDA 32 sections
Eszopiclone HUMAN PRESCRIPTION DRUG LABEL 1 0378-5272 TABLET, FILM COATED 3 mg ORAL ANDA 32 sections
Lunesta HUMAN PRESCRIPTION DRUG LABEL 1 21695-225 TABLET, COATED 2 mg ORAL NDA 30 sections
Lunesta HUMAN PRESCRIPTION DRUG LABEL 1 21695-226 TABLET, COATED 3 mg ORAL NDA 30 sections
Eszopiclone HUMAN PRESCRIPTION DRUG LABEL 1 31722-855 TABLET, FILM COATED 1 mg ORAL ANDA 31 sections
Eszopiclone HUMAN PRESCRIPTION DRUG LABEL 1 31722-856 TABLET, FILM COATED 2 mg ORAL ANDA 31 sections
Eszopiclone HUMAN PRESCRIPTION DRUG LABEL 1 31722-857 TABLET, FILM COATED 3 mg ORAL ANDA 31 sections
Eszopiclone Human Prescription Drug Label 1 33342-299 TABLET, FILM COATED 1 mg ORAL ANDA 31 sections
Eszopiclone Human Prescription Drug Label 1 33342-300 TABLET, FILM COATED 2 mg ORAL ANDA 31 sections
Eszopiclone Human Prescription Drug Label 1 33342-301 TABLET, FILM COATED 3 mg ORAL ANDA 31 sections
Eszopiclone HUMAN PRESCRIPTION DRUG LABEL 1 43063-795 TABLET, FILM COATED 3 mg ORAL ANDA 30 sections
Eszopiclone HUMAN PRESCRIPTION DRUG LABEL 1 43063-795 TABLET, FILM COATED 3 mg ORAL ANDA 30 sections
Eszopiclone HUMAN PRESCRIPTION DRUG LABEL 1 43353-185 TABLET, FILM COATED 3 mg ORAL ANDA 32 sections
Eszopiclone HUMAN PRESCRIPTION DRUG LABEL 1 43353-200 TABLET, FILM COATED 2 mg ORAL ANDA 32 sections
ESZOPICLONE HUMAN PRESCRIPTION DRUG LABEL 1 45865-828 TABLET, FILM COATED 3 mg ORAL ANDA 30 sections
ESZOPICLONE HUMAN PRESCRIPTION DRUG LABEL 1 45865-829 TABLET, FILM COATED 2 mg ORAL ANDA 30 sections
ESZOPICLONE HUMAN PRESCRIPTION DRUG LABEL 1 45865-830 TABLET, FILM COATED 1 mg ORAL ANDA 30 sections
ESZOPICLONE Human Prescription Drug Label 1 47335-586 TABLET, FILM COATED 1 mg ORAL ANDA 30 sections
ESZOPICLONE Human Prescription Drug Label 1 47335-587 TABLET, FILM COATED 2 mg ORAL ANDA 30 sections
ESZOPICLONE Human Prescription Drug Label 1 47335-588 TABLET, FILM COATED 3 mg ORAL ANDA 30 sections
Eszopiclone HUMAN PRESCRIPTION DRUG LABEL 1 50090-2606 TABLET, FILM COATED 1 mg ORAL ANDA 31 sections
ESZOPICLONE Human Prescription Drug Label 1 50090-3514 TABLET, FILM COATED 3 mg ORAL ANDA 30 sections
ESZOPICLONE Human Prescription Drug Label 1 50090-3514 TABLET, FILM COATED 3 mg ORAL ANDA 30 sections
ESZOPICLONE Human Prescription Drug Label 1 50090-3553 TABLET, FILM COATED 1 mg ORAL ANDA 31 sections
Eszopiclone HUMAN PRESCRIPTION DRUG LABEL 1 50090-3989 TABLET, FILM COATED 1 mg ORAL ANDA 30 sections
Eszopiclone HUMAN PRESCRIPTION DRUG LABEL 1 50090-5084 TABLET, COATED 3 mg ORAL ANDA 29 sections